Want to see VOR full AI Analyst Report?
Top Page
Vor Biopharma
(NASDAQ:VOR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$23.50
▲(22.01% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by weak financial performance (pre-revenue, persistent operating losses, heavy cash burn, and deeply negative equity), which increases funding risk. Technicals are a clear positive with strong trend and bullish momentum, but overbought readings temper the near-term setup. Valuation is not supportive due to a negative P/E and no dividend, while corporate events provide incremental positives (product approval-related validation and steady governance) but are secondary to the balance-sheet and cash-flow constraints.
Positive Factors
Cash runway
Vor’s cash and marketable securities balance of $466.1M plus $48.4M of recent ATM proceeds is projected to fund operations into early 2029. That multi-year runway materially reduces near-term financing pressure and supports continued Phase 3 enrollment and R&D execution without immediate dilution.
Negative Factors
Pre-revenue status
Vor reports zero revenue across all provided periods, reflecting its clinical-stage status. Without product sales, the company must rely on partners or financing to fund operations, leaving revenue visibility low and exposing the business to execution and fundraising risk until commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway
Vor’s cash and marketable securities balance of $466.1M plus $48.4M of recent ATM proceeds is projected to fund operations into early 2029. That multi-year runway materially reduces near-term financing pressure and supports continued Phase 3 enrollment and R&D execution without immediate dilution.
Read all positive factors
Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.36B
Dividend YieldN/A
Average Volume (3M)1.54M
Price to Earnings (P/E)―
Beta (1Y)4.67
Revenue GrowthN/A
EPS Growth69.48%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-325.79
Shares Outstanding59,162,292
10 Day Avg. Volume884,081
30 Day Avg. Volume1,541,414
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$34.50Price Target Upside79.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.15
Revenue Forecast (FY)N/A
Vor Biopharma Business Overview & Revenue Model
Company Description
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently unde...
How the Company Makes Money
null...
Vor Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -28.00K | 0.00 | 0.00 | -3.49M | -8.96M | 0.00 |
| EBITDA | 642.79M | -693.09M | -113.39M | -114.37M | -83.13M | -67.47M |
| Net Income | 627.78M | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
Balance Sheet | ||||||
| Total Assets | 481.05M | 464.13M | 142.89M | 209.83M | 299.37M | 242.59M |
| Cash, Cash Equivalents and Short-Term Investments | 466.13M | 455.21M | 91.93M | 137.18M | 230.25M | 207.47M |
| Total Debt | 2.88M | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Total Liabilities | 681.25M | 628.44M | 46.23M | 59.10M | 48.76M | 26.33M |
| Stockholders Equity | -200.20M | -164.31M | 96.66M | 150.72M | 250.61M | 216.26M |
Cash Flow | ||||||
| Free Cash Flow | -141.11M | -143.65M | -99.89M | -101.36M | -93.61M | -73.04M |
| Operating Cash Flow | -140.38M | -142.71M | -99.66M | -100.29M | -85.14M | -69.14M |
| Investing Cash Flow | -348.99M | -48.80M | 96.86M | 71.01M | -94.09M | -91.65M |
| Financing Cash Flow | 404.24M | 503.81M | 53.39M | 2.94M | 117.14M | 232.91M |
Vor Biopharma Technical Analysis
Positive
19.26
Price Trends
18.40
Positive
16.78
Positive
15.24
Positive
Market Momentum
1.41
Negative
62.37
Neutral
60.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 19.26 is below the 20-day moving average (MA) of 21.31, above the 50-day MA of 18.40, and above the 200-day MA of 15.24, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 62.37 is Neutral, neither overbought nor oversold. The STOCH value of 60.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.
Vor Biopharma Risk Analysis
Vor Biopharma disclosed 82 risk factors in its most recent earnings report. Vor Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vor Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.36B | -0.07 | -91.63% | ― | ― | 69.48% | |
52 Neutral | $410.65M | -2.46 | -64.25% | ― | ― | -29.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $169.39M | -1.46 | -89.11% | ― | 10.02% | 39.66% | |
48 Neutral | $116.06M | -2.73 | -38.80% | ― | -100.00% | -392.92% | |
47 Neutral | $170.83M | -4.64 | -74.36% | ― | 35.89% | 58.70% | |
46 Neutral | $505.26M | -2.78 | -81.91% | ― | ― | 20.07% |
* Healthcare Sector Average
VOR
Vor Biopharma
23.03
-17.77
-43.55%
CDXS
Codexis
1.56
-1.44
-48.00%
BDTX
Black Diamond Therapeutics
2.02
-0.73
-26.55%
AVIR
Atea Pharmaceuticals
5.12
1.59
45.04%
CRBU
Caribou Biosciences
1.58
-0.29
-15.51%
KYTX
Kyverna Therapeutics, Inc.
8.17
4.63
130.79%
Vor Biopharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
Positive
Jul 7, 2026
On July 6, 2026, Vor Biopharma announced that Board member Andrew Levin, M.D., Ph.D., resigned effective immediately, with the company noting his departure did not stem from any disagreement. The Board expressed appreciation for his service, indic...
Executive/Board ChangesShareholder Meetings
Vor Biopharma shareholders back directors and governance measures
Positive
Jun 12, 2026
At its 2026 Annual Meeting, Vor Biopharma stockholders elected Andrew Levin, M.D., Ph.D., and Fouad Namouni, M.D., as Class II directors to serve on the board until the 2029 Annual Meeting, with more than 34 million shares represented, or about 62...
Business Operations and StrategyProduct-Related Announcements
Vor Bio gains boost from telitacicept IgA nephropathy approval
Positive
Jun 8, 2026
Vor Bio and its collaborator RemeGen Co., Ltd. reported on June 8, 2026, that China’s National Medicinal Products Administration granted conditional approval for telitacicept to treat adult patients with IgA nephropathy in China. The decisio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.